North America Epigenetics Market Top Leaders: ABCAM, DIAGENODE, ILLUMINA, MERCK & CO., QIAGEN, SIGMA ALDRICH CORPORATION, THERMO FISHER SCIENTIFIC, ZYMO RESEARCH CORPORATION

North America Epigenetics Market Highlights
The North America epigenetics market is estimated to register a CAGR of around 20%, during the forecast period. Epigenetics is defined as the study of changes in gene expression, which are caused by certain base pairs in DNA, or RNA, being turned off or on again, through the chemical reactions.

Get your sample report now @ https://marketprognosis.com/sample-request/16904
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Increasing Incidence and Prevalence of Cancer
It is estimated that nearly 6% of the malignancies occur in the United States. According to the American Cancer society, nearly 40,000 people in the United States are diagnosed with head and neck cancer, of which 12,000 were supposed to die in the year 2014 alone. This depicts the large patient pool of cancer patients, which will propel the growth of the epigenetics market. As this epigenetics is used in the study of changes in gene expression which are useful in the cancer diagnosis. So, with the increasing cancer prevalence the market is expected to grow. The other factors, like increasing funding for R&D in healthcare and the rising epigenetic applications in non-oncology diseases, are driving the North America epigenetics market.

Key Developments in the Market
• December 2017 - Roche and Ignyta made definitive merger agreement and roche is planning to acquire ignyta
• December 2017 - Zymo Research collaborated with Bertin

Major Players:
ABCAM PLC, DIAGENODE INC, ILLUMINA INC, MERCK & CO., QIAGEN, SIGMA ALDRICH CORPORATION, THERMO FISHER SCIENTIFIC, ZYMO RESEARCH CORPORATION, ROCHE, among others.

Get Discount on this report @ https://marketprognosis.com/discount-request/16904
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Rising Cost of Instruments
The epigenetic instruments cost is rising gradually, and this increase is becoming one of the major restrains for the growth of the market. The instruments, such as mass spectrometers, sonicators, and the next generation sequences, are already costly, and the rising cost of these instruments are going to increase the cost for the genetic test, which simultaneously decreases the adoption rate of epigenetics. Additionally, lack of skilled researchers is restraining the North America epigenetics market.

The US has the Highest Market Share
In North America, the US is dominating the epigenetics market due to the factors, such as increasing prevalence rate of cancer, increasing funding for the R&D, and the increasing collaborations between several large pharmaceutical companies for development of enhanced therapeutics.

For More Information, Please Visit @ https://marketprognosis.com/enquiry/16904
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.